Skip to search formSkip to main contentSkip to account menu

AEE 788

Known as: AEE-788, AEE788 
An orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth… 
National Institutes of Health

Related topics

Related topics

4 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Narrower (1)

NVP-AEE788

Broader (1)

Purines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.
2011
2011
Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma
PurposeTreating glioblastoma through the simultaneous inhibition of multiple transduction pathways may prove more effective than… 
2009
2009
A screening platform for glioma growth and invasion using bioluminescence imaging. Laboratory investigation.
OBJECT The study of tumor cell growth and invasion in cancer biology is often limited by the inability to visualize tumor cell… 
2008
2008
The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice.
We investigated the effect of AEE788, a novel dual receptor tyrosine kinase inhibitor of the EGF and the VEGF receptor, for… 
2007
2007
Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells
The oncogenic epidermal growth factor receptor (EGFR) pathway triggers downstream phosphatidylinositol 3-kinase (PI3K)/RAS… 
2007
2007
Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
2006
2006
Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on…
Inhibiting epidermal growth factor receptor (EGF‐R) and vascular endothelial growth factor receptor (VEGF‐R) activation with… 
2005
2005
Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose…
3028 Background: AEE788 is an orally active, small-molecule, multitargeted kinase inhibitor with potent inhibitory activity… 
2005
2005
AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: Preliminary phase 1 results
3039 Background: AEE788 is an oral inhibitor with potent activity against multiple tyrosine kinases including EGFR, HER2, and… 
2001
2001
The uptake of iron-55 by marine sediment, macroalgae, and biota following discharge from a nuclear power station.
Significant quantities of 55Fe, an activation product of stable iron, have been released into the environment following the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)